Discovery of WAY-260022, a potent and selective inhibitor of the norepinephrine transporter

ACS Medicinal Chemistry Letters

Volumn 1, Issue 3, 2010, Pages 91-95

  Gavrin, Lori K ^a   Mahaney, Paige E ^b   Jenkins, Douglas ^b   Nogle, Lisa M ^b   Mugford, Cheryl A ^c   Huselton, Christine ^c   Leiter, Jennifer ^a   Johnston, Grace H ^a   Bray, Jenifer A ^a   Burroughs, Kevin D ^a   Cosmi, Scott A ^a   Alfinito, Peter ^a   Ho, Douglas M ^d   Deecher, Darlene C ^a   Trybulski, Eugene J ^b  

^a PFIZER INC   (United States)

^b Worldwide Medicinal Chemistry   (United States)

^c Drug Safety and Metabolism   (United States)

^d PRINCETON UNIVERSITY   (United States)

Author keywords

brain penetration; dopamine transporter; norepinephrine reuptake inhibitor; serotonin transporter; vasomotor symptoms; WAY 260022

Indexed keywords

1 [2 (3,5 DIMETHYLPIPERAZIN 1 YL) 1 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL]CYCLOHEXANOL DIHYDROCHLORIDE; 1 [2 (AMINO) 1 [3 (TRIFLUOROMETHOXY)PHENYL]ETHYL]CYCLOHEXANOL DERIVATIVE; CYCLOHEXANOL DERIVATIVE; DOPAMINE TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; NRI 022; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; WAY 260022;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; THERMOREGULATORY DYSFUNCTION; VASOMOTOR DISORDER;

RATTUS;

EID: 77953206525     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100009p     Document Type: Article

References (20)

1. Katovich, M. J.; Pitman, D. L.; Barney, C. C. Mechanisms mediating the thermal response to morphine withdrawal in rats Proc. Soc. Exp. Biol. Med. 1990, 193 (2) 129-135
2. Berendsen, H. H. G.; Weekers, A. H. J.; Kloosterboer, H. J. Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats Eur. J. Pharmacol. 2001, 419 (1) 47-54
3. Rödström, K.; Bengtsson, C.; Lissner, L.; Milsom, I.; Sundh, V.; Björkelund, C. A longitudinal study of the treatment of hot flushes: The population study of women in Gothenburg during a quarter of a century Menopause 2002, 9 (3) 156-161
4. Groeneveld, F. P. M. J.; Bareman, F. P.; Barentsen, R.; Dokter, H. J.; Drogendijk, A. C.; Hoes, A. W. Vasomotor symptoms and well-being in the climacteric years Maturitas 1996, 23 (3) 293-299
5. LaCroix, A. Z.; Burke, W. Breast cancer and hormone replacement therapy Lancet 1997, 350 (9084) 1042-1043
6. World Bank; Oxford University Press: New York, 1993.
7. Ross, R. K.; Paganini-Hill, A.; Wan, P. C.; Pike, M. C. Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin J. Natl. Cancer Inst. 2000, 92 (4) 328-332
8. Nelson, H. D.; Vesco, K. K.; Haney, E.; Fu, R.; Nedrow, A.; Miller, J.; Nicolaidis, C.; Walker, M.; Humphrey, L. Nonhormonal Therapies for Menopausal Hot Flashes: Systematic Review and Meta-analysis J. Am. Med. Assoc. 2006, 295, 2057-2071
9. Panek, D. U.; Dixon, W. R. Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnover in various brain regions J. Pharmacol. Exp. Ther. 1986, 236 (3) 646-652
10. Loprinzi, C. L.; Sloan, J. A.; Perez, E. A.; Quella, S. K.; Stella, P. J.; Mailliard, J. A.; Halyard, M. Y.; Pruthi, S.; Novotny, P. J.; Rummans, T. A. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes J. Clin. Oncol. 2002, 20 (6) 1578-1583
11. Loprinzi, C. L.; Kugler, J. W.; Sloan, J. A.; Mailliard, J. A.; LaVasseur, B. I.; Barton, D. L.; Novotny, P. J.; Dakhil, S. R.; Rodger, K.; Rummans, T. A.; Christensen, B. J. Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial Lancet 2000, 356 (9247) 2059-2063
12. Stearns, V.; Beebe, K. L.; Iyengar, M.; Dube, E. Paroxetine Controlled Release in the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial J. Am. Med. Assoc. 2003, 289 (21) 2827-2834
13. Kumar, V. N. Interrelation between thermoregulation and sleep regulation Proc. Natl. Acad. Sci., India, Sect. B 2003, 69, 507-524
14. Mahaney, P. E.; Gavrin, L. K.; Trybulski, E. J.; Stack, G. P.; Vu, A. T.; Cohn, S. T.; Ye, F.; Belardi, J. K.; Santilli, A. A.; Sabatucci, J. P.; Leiter, J.; Johnston, G. H.; Bray, J. A.; Burroughs, K. D.; Cosmi, S. A.; Leventhal, L.; Koury, E. J.; Zhang, Y.; Mugford, C. A.; Ho, D. M.; Rosenzweig-Lipson, S. J.; Platt, B.; Smith, V. A.; Deecher, D. C. Structure-activity relationships of the cycloalkanol ethylamine scaffold: Discovery of selective norepinephrine reuptake inhibitors J. Med. Chem. 2008, 51 (13) 4038-4049
15. Deecher, D. C.; Alfinito, P.; Leventhal, L.; Johnston, G. H.; Cosmi, S.; Merchenthaler, I.; Winneker, R. Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models Endocrinology 2007, 148, 1376-1383
16. Maswood, N.; Alfinito, P. D.; Cosmi, S.; Leventhal, L.; Johnston, G. H.; Deecher, D. C. Evalulation of the selective serotonin reuptake inhibitor, fluoxetine, in ovariectomized (OVX) rat models of temperature regulation Neuroendocrinology 2006, 85, 330-338
17. Waterhouse, R. N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents Mol. Imaging Biol. 2003, 5 (6) 376-389
18. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods J. Phys. Chem. A 1998, 102, 3762-3772
19. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38 (3) 223-232
20. Mathews, C. K.; van Holde, K. E. Integration and control of metabolic processes. Biochemistry; The Benjamin/Cummings Publishing Group: Redwood City, CA, 1990; pp 790-792.